A breakthrough malaria vaccine may be on the horizon. According to an article published by National Geographic, new research shows a promising vaccine to protect against malaria. The results of the study, originally published in The Lancet last month, show that the vaccine, R21, effectively protected against malaria in children. Research participants had received three shots in an eight-week period with a booster 12 months later. Read the full article here.
Vaccine research is vital for protecting target populations from disease. Vaccine research is one of Sanguine’s top priorities, which is why we partnered with researchers likes Pfizer and Vir Biotechnology to develop a COVID-19 vaccine. Sanguine’s COVID-19 efforts were published with Pfizer’s phase 1 clinical trial findings in the New England Journal of Medicine.
Clinical research has proved to be pivotal for development of the Pfizer COVID-19 vaccine and this new breakthrough malaria vaccine.